<DOC>
	<DOCNO>NCT00975676</DOCNO>
	<brief_summary>RATIONALE : Studying sample blood patient breast cancer laboratory may help doctor learn well triptorelin give together tamoxifen citrate exemestane work lower estrogen level . PURPOSE : This clinical trial study estrogen level premenopausal woman undergone surgery breast cancer receive triptorelin tamoxifen citrate exemestane clinical trial IBCSG-2402 .</brief_summary>
	<brief_title>Study Estrogen Levels Premenopausal Women Who Have Undergone Surgery Breast Cancer Are Receiving Triptorelin Tamoxifen Citrate Exemestane Clinical Trial IBCSG 24-02</brief_title>
	<detailed_description>OBJECTIVES : Primary - Describe estrogen level ( estradiol [ E2 ] , estrone [ E1 ] , estrone sulphate [ E1S ] ) different time point first 4 year treatment triptorelin combination either tamoxifen citrate exemestane clinical trial IBCSG-2402 premenopausal woman resect breast cancer . - Assess whether suboptimally estrogen-suppressed subgroup patient receive exemestane . Secondary - Compare estrogen level ( E2 , E1 , E1S ) different time point treatment triptorelin combination either tamoxifen citrate exemestane . - Examine potential predictive factor ineffective estrogen suppression ( e.g. , age , chemotherapy [ yes/no ] , type chemotherapy receive , smoke history , BMI , evidence menses study entry ) . - Investigate predictive value optimal estrogen suppression first 6 12 month treatment regard long-term estrogen suppression ( 4-year period ) . - Compare disease-free survival suboptimally estrogen-suppressed patient treat exemestane patient optimal suppression ( exploratory analysis ) . - Examine related endocrine function ( FSH LH ) elucidate cause suboptimal estrogen suppression . OUTLINE : This multicenter study . Blood sample collect baseline 3 , 6 , 12 , 18 , 24 , 36 , 48 month measurement estrogen level ( estradiol [ E2 ] , estrone [ E1 ] , estrone sulphate [ E1S ] ) gas chromatography-mass spectrometry measurement endocrine function ( FSH LH ) .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Triptorelin Pamoate</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm resect breast cancer Concurrent enrollment clinical trial IBCSG2402 ( SOFT trial ) require Randomized receive triptorelin combination either tamoxifen citrate exemestane Hormone receptor status : Estrogen receptor and/or progesterone receptorpositive tumor PATIENT CHARACTERISTICS : Premenopausal PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>estrogen receptor-positive breast cancer</keyword>
	<keyword>progesterone receptor-positive breast cancer</keyword>
	<keyword>stage IA breast cancer</keyword>
	<keyword>stage IB breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
</DOC>